- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 181987, 13 pages
Bladder Cancer Immunotherapy: BCG and Beyond
Department of Urology, University of Iowa, 375 Newton Road, 3204 MERF, Iowa City, IA 52242, USA
Received 16 March 2012; Accepted 11 May 2012
Academic Editor: Trinity J. Bivalacqua
Copyright © 2012 Eric J. Askeland et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10.
With more than 73,000 estimated cases diagnosed in 2012, bladder cancer is the fifth most common malignancy in the United States, responsible for more than 14,000 deaths per year . Urothelial carcinoma accounts for 90% of bladder tumors, of which approximately 70% are confined to layers above the muscularis propria—the so-called nonmuscle invasive bladder cancer (NMIBC). These tumors (previously termed “superficial bladder tumors”) include stages Ta, T1, and Tis, occurring in 70%, 20%, and 10% of NMIBC cases, respectively . Standard primary treatment for NMIBC is transurethral resection (TUR); however, recurrence rates for TUR alone can be as high as 70% with up to 30% progressing to muscle invasive disease requiring cystectomy .
High rates of recurrence and progression have prompted investigation into a myriad of treatments attempting to decrease the burden of this disease. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the most well known and studied of these adjunctive treatments. Since its first description in 1976 by Morales et al. , intravesical BCG has become the standard therapy for NMIBC, superior to any other single chemotherapeutic agent for reducing recurrence and preventing progression. Typical complete response rates are 55–65% for papillary tumors and 70–75% for carcinoma in situ (CIS), which inversely indicates that 30–45% of patients will be BCG failures [5–7]. Of the complete responders, up to 50% will have a recurrence . Furthermore, side effects range from cystitis and irritative voiding symptoms to much more uncommon life-threatening BCG sepsis. Up to 20% of patients are BCG intolerant due to these side effects .
Understanding of BCG, both its mechanisms (which remain incompletely characterized) and its obvious limitations, is critical to improving the efficacy of therapy. The initial step after BCG instillation is binding of BCG to fibronectin expressed on the urothelium, after which the mycobacterium is internalized by both normal and malignant cells, resulting in urothelial activation and subsequent inflammatory responses in the bladder . BCG antigens can be presented at the cell surfaces of urothelial and antigen-presenting cells in the context of major histocompatibility complex (MHC) class II, stimulating CD4+ T cells and inducing a primarily T helper type (Th) 1 immune response . This complex and robust immune reaction evoked by BCG is evidenced by a massive transient secretion of cytokines in voided urine, including interleukin (IL)-1, IL-2, IL-5, IL-6, IL-8, IL-10, IL-12, IL-15, IL-18, interferon-inducible protein (IP)-10, tumor necrosis factor (TNF)-α, granulocyte-monocyte colony stimulating factor (GMCSF), and interferon (IFN)-γ . While the role each of these cytokines plays in urothelial carcinoma treatment is not completely clear, Th1 cytokines (e.g., IFN-γ, IL-2, and IL-12) have been associated with BCG response, while Th2 cytokines (e.g., IL-10 and IL-6) correlate with BCG failure, as illustrated in Figure 1 [13–16]. Since the advent of BCG therapy, a significant amount of data has accumulated to support maintenance treatments, which typically consist of a series of shorter treatments at 3–6-month intervals, often based on the time table developed by the Southwest Oncology Group .
While success has improved with the addition of maintenance treatments, the combination of intravesical therapy, surveillance, and repeat surgical procedures place enormous costs on the US healthcare system, approaching $4 billion annually . Prompted by the burden of patients either with BCG refractory disease or who are intolerant of treatment, the search goes on for therapeutic improvements. Given that the effect of BCG is immune mediated, decades of research have focused on adjunctive immunotherapies including IFN-, IL-2, IL-10, and IL-12. This paper summarizes and integrates key points for the clinical urologic oncologist.
Interferons (IFNs) are glycoproteins initially isolated in the 1950s and valued for their antiviral properties. Three types have been isolated, IFN- (which is actually a family of interferons), IFN-β, and IFN-γ. IFN- and IFN-β are grouped as “Type I” interferons, whereas IFN-γ is a “Type II” interferon. The Type I interferon receptor has 2 components, IFNAR-1 and IFNAR-2, which subsequently bind and phosphorylate Jak molecules initiating a cascade resulting in gene transcription . The IFN-α family is well known to stimulate natural killer (NK) cells, induce MHC class I response, and increase antibody recognition . They have antineoplastic properties by direct antiproliferative effects and complex immunomodulatory effects , both of which could be advantageous for bladder cancer treatment. Clinically available preparations include IFN-α2a (Roferon-A, Roche Laboratories, Nutley, NJ) and IFN-α2b (Intron-A, Schering Plough, Kenilworth, NJ), though to date most research involves IFN-α2b. There has been interest in IFN-α2b both alone and in combination with BCG, where a synergistic response has been described. Conceptually, combining BCG and IFN makes sense. BCG efficacy depends on the induction of a robust Th1 cytokine profile, and IFN-α2b has been shown to potentiate the Th1 immune response . However, despite theoretical promise, data after translation to clinical practice has been mixed.
For many years, IFN-α was thought to exert antitumor activity primarily through direct antiproliferative properties . At least part of this effect has been shown to be mediated by directly inducing tumor cell death. IFN-α has been documented to independently induce Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) expression in UM-UC-12 bladder cancer cells , which subsequently triggers apoptosis in cells expressing the appropriate cell death receptor. Cell death occurs ultimately by Fas-associated protein with death-domain- (FADD-) dependent activation of the death inducing signaling complex (DISC) followed by activation of caspase-8. Furthermore, Tecchio and colleagues have demonstrated that IFN-α can stimulate TRAIL mRNA as well as the release of a bioactive soluble TRAIL protein from neutrophils and monocytes, which induces apoptotic activity on TRAIL-sensitive leukemic cell lines . It also appears that IFN-α apoptotic effects may not be limited to TRAIL; rather it may trigger caspase-8 via both cell death receptor-dependent and independent pathways . Much like IFN-α, BCG has also been shown to induce TRAIL , which has correlated with patient response to BCG therapy and has been a source of overlapping research interest. Other direct IFN-α effects include enhancing cytotoxicity of CD4+ T cells, increasing antigen detection by upregulating MHC class I expression [20, 25, 26]. Direct suppression of proliferation by induction of tumor suppressor genes or inhibition of tumor oncogenes has also been described . Also contributing to antiproliferative properties, IFN-α has been documented to decrease angiogenesis and basic fibroblast growth factor. Additionally, it downregulates matrix metalloprotease-9 (MMP-9) mRNA as well as the MMP-9 translational protein in murine bladder tumors . Interestingly, it has also been demonstrated that an optimal biologic dose with higher frequency, rather than maximal tolerated dose, produced the most significant decreases in angiogenesis. Significantly decreased angiogenesis has also been documented in human urothelium during and after IFN-α2b treatment following transurethral resection of superficial bladder tumors .
In vivo monotherapy with IFN-α2b for bladder cancer in humans has been explored by multiple groups. In 1990, Glashan published data from a randomized controlled trial evaluating high dose (100 million unit) and low dose (10 million unit) IFN-α2b regimens in patients with CIS . Patients were treated weekly for 12 weeks and monthly thereafter for 1 year. The high and low dose groups had complete response rates of 43% and 5%, respectively. Of the high dose patients achieving a complete response, 90% remained disease-free at a notably short 6 months of follow-up. The primary side effects of treatment were flu-like symptoms (8% low dose, 17% high dose) but without the irritative symptoms seen so often in BCG therapy. When IFN-α2b was investigated alone to treat BCG failures, eight of twelve patients had recurrence at initial three-month evaluation and only one of twelve was disease-free at 24 months . Another trial conducted by Portillo and colleagues randomized 90 pT1 bladder cancer patients to either intravesical treatment or placebo groups as primary prophylaxis after complete resection . They utilized a similar dosing schedule but used 60 million units IFN-α2b. At 12 months of followup, recurrence rates were significantly lower for IFN-α2b group than placebo, 28.2% versus 35.8%, respectively. However, after 43 months, rates were similar—53.8% and 51.2%, respectively, indicating that treatment benefit of IFN-α2b alone may not be durable.
Given the described antiproliferative and immunomodulatory effects of IFN-α, combination therapy with BCG has held tantalizing promise. Gan et al. found significantly greater antitumor activity with combination therapy than BCG alone: 14/15 mice receiving BCG/IFN-α versus 8/15 mice receiving only BCG became tumor-free after 5 weekly intralesional treatments . In an in vitro study comparing BCG plus IFN-α to BCG alone, our group demonstrated a 66-fold increase in IFN-γ production in peripheral blood mononuclear cell (PBMC) cultures . Since IFN-γ is a major Th1-restricted cytokine found in patients responding to BCG therapy, it has been used routinely as a surrogate marker for Th1 immune response in studies examining effect of IFN-α . It appears that IFN-α by itself generates a negligible Th1 response, as no significant levels of IFN-γ were detected after IFN-α was incubated alone with the PBMCs. We have also demonstrated that the augmented IFN-γ production persisted even with reduced doses of BCG. These findings give credence to the idea that adding Th1-stimulating cytokines may allow for a decrease in BCG doses, thereby decreasing side effects thought to be directly related to BCG. Further augmenting Th1 differentiation, IFN-α was found to increase levels of several Th1 cytokines, including IL-12 and TNF-α as well as decreasing known Th1 inhibitory cytokines IL-10 and IL-6 by 80–90% and 20–30%, respectively .
Clinical investigations with the combination of IFN-α2b and BCG began initially in BCG refractory patients but were subsequently expanded to BCG naïve patients. Stricker et al. found the combination to be safe, with a similar side effect profile to BCG alone . In 2001, O’Donnell and colleagues reported on combination therapy administered to 40 patients who had failed at least 1 course of BCG alone . At 24 months, 53% of patients were disease-free. Patients with two or more prior BCG failures faired similarly to patients with only one. Lam et al. in 2003 reported on the treatment of 32 patients, of which 20 (63%) were BCG failures. At 22 months’ median followup, 12 of the 20 BCG failure patients (60%) remained disease-free . In a smaller trial, Punnen et al. documented a 50% disease-free rate after combination therapy at 12 months’ followup in 12 patients with BCG refractory disease . A subsequent large community-based phase II clinical trial examined 1106 patients from 125 sites with NMIBC, which were split into BCG naïve and BCG refractory groups . At median 24 months’ followup, tumor-free rates were 59% and 45%, respectively. In this larger trial, patients who had two or more courses of prior BCG therapy had a worse outcome when compared to patients who had 1 or less, likely indicating more resistant disease. A recent study limited to BCG naïve patients demonstrated similar disease-free rate of 62% but with much longer median followup of 55.8 months . Furthermore, after evaluating failure patterns and response rates to BCG plus IFN-α, Gallagher et al. found that patients who recurred more than 12 months after initial BCG treatments had similar tumor-free rates at 24 months when compared to BCG naïve patients . However, patients who recurred within a year of receiving their initial BCG treatments did significantly worse, with disease-free rates of 34–43% at 24 months, indicating that additional immunotherapy may not be appropriate. Overall, while promising, these data are unable to define any treatment benefit of combination therapy over BCG alone.
To date, the only randomized trial comparing BCG alone to BCG plus IFN-α was a multicenter study of 670 BCG naïve patients with CIS, Ta, or T1 urothelial carcinoma . This was a four-arm trial evaluating efficacy of megadose vitamins as well as BCG and IFN. Patients were randomized to 1 of 4 groups: BCG plus recommended daily vitamins, BCG plus megadose daily vitamins, BCG plus IFN-α2b plus recommended daily vitamins, and BCG plus IFN-α2b plus megadose daily vitamins. At 24-month followup, median recurrence-free survival was similar across all groups, though the two IFN-2b groups experienced higher incidence of constitutional symptoms and fever (P < 0.05).
Lastly, there are multiple areas where additional research is warranted. A recent evolution in combination therapy has been the development of an IFN-2b expressing strain of recombinant BCG (rBCG-IFN-) from the Pasteur strain of BCG. An initial in vitro study documented enhanced IFN- expression in PBMCs after incubation with rBCG-IFN- as compared to standard BCG . A subsequent study reported that rBCG-IFN- increased cytotoxicity up to 2-fold over standard BCG in PBMC cultures. Both CD56+CD8- NK cells and CD8+ T cells were identified as primary contributors to the increased cytotoxicity . Combining IFN-2b with other antiproliferative agents has shown in vitro promise. Louie et al. reported that a combination of IFN-2b and maitake mushroom D-fraction (PDF) could reduce T24 bladder cancer cell proliferation by 75%, accompanied by G1 cell cycle arrest . Another combination recently published this year documented that adding grape seed proanthocyanin significantly enhanced antiproliferative effects of IFN-α2b, with >95% growth reduction in T24 bladder cancer cells. Cell cycle analysis also revealed G1 cell cycle arrest, with Western blots confirming expression of G1 cell cycle regulators . Lastly, several groups have investigated gene therapy with a recombinant adenovirus delivery system (rAd-IFN/Syn3), which could potentially result in sustained therapeutic IFN-2b levels for long periods of time. Nagabhushan et al. were able to demonstrate delivery and expression of IFN in the bladder as well as significant tumor regression in mice. Phase I trials with rAd-IFN/Syn3 were ongoing at the time of their publication in 2007 .
The discovery and characterization of interleukin-2 (IL-2) was one of the most important breakthroughs in the field of immunology. Prior to its discovery, lymphocytes were thought to be terminally differentiated and incapable of proliferation [47, 48]. In 1975, it was discovered that the supernatant of murine splenic cell cultures could stimulate thymocytes, suggesting a native effector protein was responsible for this mitogenic activity [48, 49]. When initially examined independently by different investigators, this “effector protein” was given multiple working names including thymocyte-stimulating factor (TSF), thymocyte mitogenic factor (TMF), T cell growth factor (TCGF), costimulator, killer cell helper factor (KHF), and secondary cytotoxic T-cell-inducing factor (SCIF) . In 1979, it was recognized that these factors likely represented the same entity, and the nomenclature was standardized with the term “interleukin” (between leukocytes). Thus, the “effector protein” was named IL-2, differentiating it from the only other interleukin known at that time, IL-1 . Regardless of the nomenclature, this protein was recognized to promote proliferation of primary T cells in vitro, which revolutionized the experimental armamentarium in the field of immunology [47, 49, 51].
Since the discovery of IL-2-mediated control of T-cell growth in culture, there has been much progress in elucidating its mechanisms. It was discovered relatively early that IL-2 enhances the production of cytotoxic lymphocytes which are capable of lysing tumor cells while leaving normal cells unharmed [51–53]. These IL-2 activated lymphocytes became known as “lymphokine-activated killer” (LAK) cells and were thought to play a large role in antitumor immune function [51–53]. Additionally, it was noted that IL-2 functions to augment the cytotoxic activity of NK cells and monocytes [54, 55]. It has even been discovered that IL-2 is important for the activation of B cells . As the CD4+ Th1 and Th2 cell cytokine profiles were defined, it became clear that IL-2 is predominantly a Th1-secreted cytokine .
The cytotoxic antitumor capabilities induced in lymphocytes by IL-2 make it a potential cancer immunotherapeutic agent. To date, multiple studies have demonstrated regression of metastatic disease following systemic IL-2 treatment in some cancers . Rosenberg et al. reported on 157 patients with a heterogenous mix of metastatic cancers refractory to other treatments including renal cell, colon cancer, breast cancer, and lymphoma. Patients were treated with either IL-2 and LAK cells or IL-2 alone. Between the two groups, 9 complete and 20 partial responses were obtained. Significant morbidity has been reported with systemic IL-2 much of which is secondary to increased capillary permeability [58, 59] and includes weight gain, hypotension, oliguria, elevated creatinine, and bilirubin. These tend to resolve with cessation of IL-2 therapy ; however, Rosenberg reported 4 treatment-related deaths among their 157 patients. Despite the reports of morbidity, IL-2 seemed to offer hope to patients with few treatment options.
With regard to bladder cancer, interest was stimulated after multiple investigators identified elevated IL-2 levels (as well as other cytokines) in urine of patients following BCG, suggesting an immunomodulatory effect of BCG [60–67]. Additionally, an elevation in IL-2 receptor expression has been documented on T cells in voided urine after BCG therapy [64, 66]. Increased levels of urinary IL-2 have also been found to correlate with BCG response, which supports the concept that a Th1 cytokine profile confers a favorable response to BCG . Furthermore, elevated IL-2 has been reported in the serum of patients following BCG instillation, which suggests both a local and systemic immune response to therapy [68, 69]. These findings led to the conclusion that IL-2 may have a therapeutic use in bladder cancer.
One of the first clinical trials reported evidence of bladder tumor regression following intralesional injections of IL-2, with no adverse events recorded . Multiple murine studies have demonstrated that systemic administration of IL-2, with or without BCG, can significantly decrease tumor size, suppress tumor growth, and improve mean survival [71–73]. A small clinical study investigating systemic IL-2 administration effects on low-stage bladder cancer found a complete and partial response rate in 5 of 12 patients, though 2 patients discontinued therapy due to toxicity . The poor side effect profile of systemic IL-2 administration subsequently prompted a shift to utilize IL-2 as an intravesical therapy. Reports of intravesical use revealed a much improved side effect profile as well as some efficacy alone or when combined with BCG [75–78]. Den Otter et al. administered intravesical IL-2 alone after incomplete transurethral resection of grade 1-2, T1 papillary urothelial carcinoma, and documented “marker lesion” regression in 8 of 10 patients . Additional experiments have focused on developing recombinant-IL-2-secreting strains of BCG [80–85]. Animal models using this approach have shown that compared to native BCG, IL-2-secreting BCG strains have increased IFN-γ production, induced a more favorable IFN-γ to IL-4 ratio, improved antigen-specific proliferation, enhanced antitumor cytotoxicity, and mounted a Th1 cytokine profile even in immunosuppressed or IL-4 transgenic mice (two conditions which favor a Th2 response) [80–83, 85]. More recent animal and in vitro studies have investigated IL-2 transfecting dendritic cells (DCs), immobilized streptavidin-tagged bioactive IL-2 on the biotinylated surface of murine bladder mucosa, and development of a murine IL-2 surface modified bladder cancer vaccine [86–89]. Since IL-2 plays a crucial role in the Th1 response, it will continue to be a source of interest for immunotherapy of bladder cancer.
Interleukin-12 (IL-12) has been the focus of significant cancer research among cytokines as well. In 1987, it was discovered through in vitro experiments that there existed a factor which synergized with IL-2 in promoting a cytotoxic T lymphocyte (CTL) response . This factor was given the name cytotoxic lymphocyte maturation factor (CLMF) . Shortly thereafter a factor was discovered that induced IFN-γ production, enhanced T cell responses to mitogens, and augmented NK cell cytotoxicity . This factor was provisionally called natural killer cell stimulatory factor (NKSF) . It did not take long to discover that these factors represented the same entity, thus the nomenclature converged and this protein was termed IL-12 [91–95].
Although initially discovered in a B cell lymphoma, it was subsequently found that IL-12 is primarily involved with the regulation of T cells, causing proliferation of both activated CD4+ and CD8+ T cell subsets while causing minimal proliferation of resting PBMCs [90, 92]. This concept is supported by studies demonstrating that the IL-12 receptor is upregulated in activated T and NK cells, but not in activated B cells . IL-12 potentiates a Th1-specific immune response, and it was later discovered that DCs produce IL-12 and thus direct the development of Th1 cells from naïve CD4+ T cells [96, 97]. Additionally, IL-12 can, by itself, stimulate the activation of nonspecific LAK cells and facilitate the generation of an allogeneic CTL response . IL-12 has even been found to play a role in the activation of neutrophils [99, 100]. Multiple studies have demonstrated that IL-12 strongly inhibits neovascularization, thought to be mediated through its induction of IFN-γ [101–104]. Furthermore, the mechanism by which IL-12 enhances the cytolytic effect of NK cells is primarily via the perforin pathway [105, 106].
Multiple animal studies have shown tumor responsiveness to immunomodulation with IL-12. Using systemic or peritumoral injections, IL-12 showed antitumor properties in murine sarcoma, melanoma, renal cell carcinoma, lung cancer, colon cancer, breast cancer, and bladder cancer models [102, 107–111]. Increases in serum IFN-γ were observed in mice treated with IL-12 . Antitumor efficacy was lost in CD8+-depleted mice, but not CD4+-depleted mice or NK-deficient mice, suggesting that the primary mediators of the antitumor IL-12 effect are CD8+ T cells [107, 108]. Some of these studies saw effectiveness even with metastatic disease, including bladder cancer [107, 108, 111]. Multiple murine studies have also revealed added effectiveness with IL-12 administered in combination with chemotherapeutic agents [109, 112–114]. Additionally, IL-12 therapy has shown synergistic activity when combined with radiation therapy in mice [110, 115]. Various delivery systems for IL-12 therapy have been tested in mice using viral and retroviral vectors to elicit an IL-12 response [116–120]. These constructs have shown some effectiveness as anticancer therapeutics [116–119]. IL-12 as an intravesical therapy for bladder cancer has shown great success in mouse models. BCG was found to be a potent stimulus for IL-12 expression, and neutralization of IL-12 significantly dampened the induction of IFN-γ by BCG . BCG therapy for murine bladder cancer was essentially found to be ineffective in IL-12 knock-out mice, suggesting a crucial role for IL-12 in the BCG response . When IL-12 is used as a therapy with BCG, it causes a synergistic induction of IFN-γ . Intravesical IL-12 treatment alone was found to be effective for the treatment of orthotopically placed bladder tumors in mice, and urinary IFN-γ was subsequently found to be significantly elevated [111, 123]. These observations further support the importance of IFN-γ induction for effective immunotherapy of bladder cancer. More recently, multiple attempts have been made to improve the delivery of intravesical IL-12 to the bladder mucosa to improve efficacy. One method utilized cationic liposome-mediated IL-12 gene therapy, which showed improved survival and tumor-specific immunologic memory in mice . Another method utilized chitosan, a mucoadhesive biopolymer, to increase IL-12 delivery to urothelial surfaces . This method showed improved efficacy over IL-12 alone in a mouse model .
The great success of IL-12 in treating various murine cancers subsequently led to experiments testing its use on human cancers, though with mixed success. Initial trials focused on systemic IL-12 treatment for metastatic cancer, though progress was initially halted when several patients suffered severe toxic effects from the treatment and two patients died from the therapy . A phase I trial of systemically administered IL-12 in 40 patients with advanced malignancy found a dose-dependent increase in circulating IFN-γ with administration . Experiments on the peripheral blood of these patients showed augmented NK cell cytolytic activity and enhanced T cell proliferation . Unfortunately, of these 40 patients there was only one partial response and one transient complete response . Further studies looking at chronic administration of twice weekly IL-12 in patients with metastatic cancer found that it is well tolerated and induces costimulatory cytokines (including IFN-γ) . However, in a cohort of 28 patients, there was only one patient with a partial response and two with prolonged disease stabilization, with one of these patients eventually exhibiting tumor regression . Similar low response rates have been seen with systemic IL-12 in other studies of advanced malignancies [130–134]. Various combinations of immunotherapy have been tested with systemic IL-12 in humans. A phase I study examined systemic IL-12 with low dose IL-2 and showed it was well tolerated, and the addition of IL-2 significantly augmented IFN-γ production as well as the NK response . Of 28 patients, there was one partial response and two pathologic responses . Another phase I study using systemic IL-12 with IFN-α2b showed acceptable toxicity, but with no response in 41 patients . As discussed previously, intravesical IL-12 showed great promise for the topical treatment of bladder cancer in a mouse model; however, this success did not translate clinically in humans. A phase I study of intravesical IL-12 therapy in patients with superficial bladder cancer showed minimal toxicity, but disappointing efficacy . A total of 15 patients were enrolled in this study, of which 12 had no visible pretreatment lesions . Of these 12 patients, 7 remained disease-free and 5 had recurrence within 4 weeks. The remaining 3 patients with pretreatment lesions had persistent disease at followup . Perhaps the most disparaging results were that there was negligible IFN-γ-induced in the urine and serum of these patients post-treatment, suggesting minimal immunologic effect from intravesical IL-12 therapy . Despite the disappointing results from human studies, IL-12 remains an important target for the treatment of bladder cancer.
Unlike other cytokines previously discussed, interleukin-10 (IL-10) is distinct in that its primary effect is to promote a Th2 response and thus dampen the immunotherapeutic effects of BCG for the treatment of bladder cancer [54, 138, 139]. As a result, it may have therapeutic value not by its native function, but by abrogation of its native function. IL-10 was first characterized in 1989. It was initially termed cytokine synthesis inhibitory factor (CSIF), a rather fitting name, because it was found to inhibit the production of several cytokines produced by Th1 clones . The most important of these cytokines was IFN-γ, which was recognized as an important player in the Th1 response. As discussed previously, it is a key contributor in the immunotherapeutic effectiveness of BCG [140, 141]. Further studies showed that IL-10 prevented a delayed-type hypersensitivity (DTH) response to BCG and the neutralization or abrogation of IL-10 prolonged a response, thus further supporting its role in the Th1/2 response [138, 142]. Several human tumors, including melanoma, non-small-cell lung carcinoma, renal cell carcinoma, and bladder cancer, have been found to express elevated levels of IL-10 [143–147]. It is speculated that production of IL-10 by tumor cells may represent an “escape mechanism” whereby tumor cells avoid Th1-immune-mediated tumoricidal effects .
There has been significant progress in determining the regulation and mechanism of IL-10 function since its discovery, particularly with regard to its role in tumor immunology. It is secreted by multiple cell types including Th2 cells, B cells, and monocytes/macrophages [140, 148–150]. Like many other cytokines, IL-10 is known to autoregulate itself by downregulating its own mRNA synthesis . It has been shown to block the accumulation of macrophages and DCs at tumor sites, which are important players in the cellular immune response [151, 152]. Additionally, it compromises DCs ability to stimulate T-cells causing induction of antigen-specific anergy of T cells . Furthermore, it down-regulates the expression of MHC class II and costimulatory molecules, thus preventing a cellular immune response to tumor cells [154–156]. During activation of CD4+ T cells, the presence of IL-10 can cause them to differentiate into T regulatory cells 1 (Tr1), leading to peripheral tolerance . IL-10 further reduces cellular tumoricidal activity by preventing release of reactive nitrogen/oxygen intermediates by macrophages and NK cells, a key step in their efficacy during cellular immune defense [139, 158].
Successful treatment of bladder cancer with BCG, as discussed previously, requires a Th1 cytokine profile. IL-10 antagonizes the production of a Th1 milieu, thus its neutralization has been targeted as a potential means to augment the BCG response. Several murine studies have demonstrated that after IL-10 knockout mice are inoculated with bladder cancer, they have an improved BCG and local immune response, increased bladder mononuclear infiltrate, enhanced DTH responses, greater antitumor activity, and prolonged survival [54, 138, 143]. Although murine IL-10 knockout studies are conceptually important, studies focused on IL-10 neutralization hold more promise as clinically useful therapeutics. Murine bladder cancer studies utilizing anti-IL-10 neutralizing antibody have shown similar results, with BCG treatment inducing an enhanced DTH response and increased bladder mononuclear infiltrate [138, 142]. More recent efforts have been placed at targeting the IL-10 receptor. The IL-10 receptor is composed of two known subunits (IL-10R1 and IL-10R2), and the IL-10R1 subunit plays the predominant role in signal transduction . In in vitro studies, we have recently shown that splenocytes incubated with BCG and anti-IL-10-receptor 1 monoclonal antibody (anti-IL-10R1 mAb) produced significantly higher IFN-γ than those incubated with BCG plus anti-IL-10-neutralizing antibody, suggesting that interference with IL-10 signal transduction may be more effective than neutralizing IL-10 protein (17). In in vivo studies, mice treated with BCG and anti-IL-10R1 mAb showed increased urinary IFN-γ production compared to BCG controls . In a similar murine experiment, there was improved overall and tumor-free state in mice treated with BCG plus anti-IL-10R1 mAb compared to BCG treatment controls, though this difference did not reach statistical significance . Most recently, in an experiment designed to follow murine survival after inoculation with a luciferase-expressing MB49 bladder cancer cells, we discovered that control mice and BCG-only treated mice developed histologically confirmed lung metastasis, whereas mice treated with BCG and anti-IL-10R1 mAb developed no metastasis [unpublished data]. This difference was statistically significant and raises questions as to anti-IL-10R1 mAb’s role as more than just an augmentation to BCG for local bladder cancer control. Confirmatory experiments and mechanistic studies are necessary, but anti-IL-10R1 mAb shows great potential in not only local bladder cancer control, but also possibly systemic immunomodulation for the prevention of metastatic bladder cancer.
Bladder cancer is a disease that places significant social and financial burdens both on the patient and on society, costing nearly $4 billion annually in the U.S. BCG, which stimulates a robust immune response in most patients and has become the standard of care after surgical resection of nonmuscle invasive disease. However, despite treatment, a significant portion of patients still recur or are intolerant of BCG side effects. Multiple immunotherapies including IFN-α, IL-2, IL-12, and IL-10 have been investigated, either as adjuncts with BCG or as a solo replacement therapy. To date, there are a multitude of encouraging in vitro and murine studies; however, no clinical data has yet been reported, which is compelling enough to change the standard of care, yet many practitioners continue to use adjunctive immunotherapy based on basic science data and theoretical benefit. At our institution, for instance, BCG or BCG/IFN- refractory disease is often treated with “quadruple therapy”—a combination of BCG, IFN-, IL-2, and GM-CSF. The widespread use of immunotherapy for bladder cancer highlights the need for additional basic science and clinical research to further our understanding of tumor biology, human immunology, and the treatment of urothelial carcinoma.
E. J. Askeland and M. R. Newton contributed equally to the production of this paper.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.
- J. Y. Ro, G. A. Staerkel, and A. G. Ayala, “Cytologic and histologic features of superficial bladder cancer,” Urologic Clinics of North America, vol. 19, no. 3, pp. 435–453, 1992.
- T. J. Kemp, A. T. Ludwig, J. K. Earel et al., “Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L,” Blood, vol. 106, no. 10, pp. 3474–3482, 2005.
- A. Morales, D. Eidinger, and A. W. Bruce, “Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors,” Journal of Urology, vol. 116, no. 2, pp. 180–183, 1976.
- M. C. Hall, S. S. Chang, G. Dalbagni et al., “Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update,” Journal of Urology, vol. 178, no. 6, pp. 2314–2330, 2007.
- D. L. Lamm, B. A. Blumenstein, E. D. Crawford et al., “A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder,” New England Journal of Medicine, vol. 325, no. 17, pp. 1205–1209, 1991.
- A. Morales, P. Ottenhof, and L. Emerson, “Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin,” Journal of Urology, vol. 125, no. 5, pp. 649–651, 1981.
- P. U. Malmström, H. Wijkström, C. Lundholm et al., “5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma,” Journal of Urology, vol. 161, no. 4, pp. 1124–1127, 1999.
- A. P. M. Van der Meijden, R. J. Sylvester, W. Oosterlinck, W. Hoeltl, and A. V. Bono, “Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial,” European Urology, vol. 44, no. 4, pp. 429–434, 2003.
- L. R. Kavoussi, E. J. Brown, J. K. Ritchey, and T. L. Ratliff, “Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response,” Journal of Clinical Investigation, vol. 85, no. 1, pp. 62–67, 1990.
- T. C. M. Zuiverloon, A. J. M. Nieuweboer, H. Vékony, W. J. Kirkels, C. H. Bangma, and E. C. Zwarthoff, “Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review,” European Urology, vol. 61, no. 1, pp. 128–145, 2012.
- Y. Luo, X. Chen, and M. A. O'Donnell, “Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect,” Cytokine, vol. 21, no. 1, pp. 17–26, 2003.
- R. Kaempfer, L. Gerez, H. Farbstein et al., “Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression,” Journal of Clinical Oncology, vol. 14, no. 6, pp. 1778–1786, 1996.
- G. N. Thalmann, A. Sermier, C. Rentsch, K. Möhrle, M. G. Cecchini, and U. E. Studer, “Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin,” Journal of Urology, vol. 164, no. 6, pp. 2129–2133, 2000.
- F. Saint, J. J. Patard, P. Maille et al., “Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer,” Journal of Urology, vol. 167, no. 1, pp. 364–367, 2002.
- T. M. De Reijke, E. C. De Boer, K. H. Kurth, and D. H. J. Schamhart, “Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value,” Journal of Urology, vol. 155, no. 2, pp. 477–482, 1996.
- D. L. Lamm, B. A. Blumenstein, J. D. Crissman et al., “Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study,” Journal of Urology, vol. 163, no. 4, pp. 1124–1129, 2000.
- E. Jonasch and F. G. Haluska, “Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities,” Oncologist, vol. 6, no. 1, pp. 34–55, 2001.
- A. M. Kamat and D. L. Lamm, “Immunotherapy for bladder cancer,” Current urology Reports, vol. 2, no. 1, pp. 62–69, 2001.
- F. Belardelli, M. Ferrantini, E. Proietti, and J. M. Kirkwood, “Interferon-alpha in tumor immunity and immunotherapy,” Cytokine and Growth Factor Reviews, vol. 13, no. 2, pp. 119–134, 2002.
- A. Papageorgiou, L. Lashinger, R. Millikan et al., “Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells,” Cancer Research, vol. 64, no. 24, pp. 8973–8979, 2004.
- C. Tecchio, V. Huber, P. Scapini et al., “IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells,” Blood, vol. 103, no. 10, pp. 3837–3844, 2004.
- A. Papageorgiou, C. P. N. Dinney, and D. J. McConkey, “Interferon-α induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells,” Cancer Biology and Therapy, vol. 6, no. 6, pp. 872–879, 2007.
- A. T. Ludwig, J. M. Moore, Y. Luo et al., “Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity,” Cancer Research, vol. 64, no. 10, pp. 3386–3390, 2004.
- M. J. Droller and D. Gomolka, “Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer,” Journal of Urology, vol. 129, no. 3, pp. 625–629, 1983.
- P. Parronchi, M. De Carli, R. Manetti et al., “IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones,” Journal of Immunology, vol. 149, no. 9, pp. 2977–2983, 1992.
- J. W. Slaton, P. Perrotte, K. Inoue, C. P. N. Dinney, and I. J. Fidler, “Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule,” Clinical Cancer Research, vol. 5, no. 10, pp. 2726–2734, 1999.
- A. Giannopoulos, I. Adamakis, K. Evangelou et al., “Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma,” Onkologie, vol. 26, no. 2, pp. 147–152, 2003.
- R. W. Glashan, “A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder,” Journal of Urology, vol. 144, no. 3, pp. 658–661, 1990.
- M. A. Hudson and T. L. Ratliff, “Failure of intravesical interferon-alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG Therapy,” Urologic Oncology, vol. 1, no. 3, pp. 115–118, 1995.
- J. Portillo, B. Martin, R. Hernandez et al., “Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder,” Urology, vol. 49, no. 2, pp. 187–190, 1997.
- Y. H. Gan, Y. Zhang, H. E. Khoo, and K. Esuvaranathan, “Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer,” European Journal of Cancer, vol. 35, no. 7, pp. 1123–1129, 1999.
- Y. Luo, X. Chen, T. M. Downs, W. C. DeWolf, and M. A. O'Donnell, “IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy,” Journal of Immunology, vol. 162, no. 4, pp. 2399–2405, 1999.
- P. Stricker, K. Pryor, T. Nicholson et al., “Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer,” Urology, vol. 48, no. 6, pp. 957–962, 1996.
- M. A. O'Donnell, J. Krohn, and W. C. DeWolf, “Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed,” Journal of Urology, vol. 166, no. 4, pp. 1300–1304, 2001.
- J. S. Lam, M. C. Benson, M. A. O'Donnell et al., “Bacillus Calmete-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity,” Urologic Oncology, vol. 21, no. 5, pp. 354–360, 2003.
- S. P. Punnen, J. L. Chin, and M. A. Jewett, “Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy,” The Canadian Journal of Urology, vol. 10, no. 2, pp. 1790–1795, 2003.
- F. N. Joudi, B. J. Smith, and M. A. O'Donnell, “Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer,” Urologic Oncology, vol. 24, no. 4, pp. 344–348, 2006.
- S. Bazarbashi, H. Soudy, M. Abdelsalam et al., “Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder,” British Journal of Urology International, vol. 108, no. 7, pp. 1115–1118, 2011.
- B. L. Gallagher, F. N. Joudi, J. L. Maymí, and M. A. O'Donnell, “Impact of previous Bacille Calmette-Guérin failure pattern on subsequent response to Bacille Calmette-Guérin plus interferon intravesical therapy,” Urology, vol. 71, no. 2, pp. 297–301, 2008.
- K. G. Nepple, A. J. Lightfoot, H. M. Rosevear, M. A. O'Donnell, and D. L. Lamm, “Bacillus Calmette-Guréin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer,” Journal of Urology, vol. 184, no. 5, pp. 1915–1919, 2010.
- Y. Luo, X. Chen, R. Han, and M. A. O'Donnell, “Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity,” Clinical and Experimental Immunology, vol. 123, no. 2, pp. 264–270, 2001.
- W. Liu, M. A. O'Donnell, X. Chen, R. Han, and Y. Luo, “Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro,” Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1647–1655, 2009.
- B. Louie, S. Rajamahanty, J. Won, M. Choudhury, and S. Konno, “Synergistic potentiation of interferon activity with maitake mushroom d-fraction on bladder cancer cells,” British Journal of Urology International, vol. 105, no. 7, pp. 1011–1015, 2010.
- A.I. Fishman, B. Johnson, B. Alexander, J. Won, M. Choudhury, and S. Konno, “Additively enhanced antiproliferative effect of interferon combined with proanthocyanidin on bladder cancer cells,” Journal of Cancer, vol. 3, pp. 107–112, 2012.
- T. L. Nagabhushan, D. C. Maneval, W. F. Benedict et al., “Enhancement of intravesical delivery with Syn3 potentiates interferon-α2b gene therapy for superficial bladder cancer,” Cytokine and Growth Factor Reviews, vol. 18, no. 5-6, pp. 389–394, 2007.
- S. Gillis and K. A. Smith, “Long term culture of tumour specific cytotoxic T cells,” Nature, vol. 268, no. 5616, pp. 154–156, 1977.
- G. Di Sabato, D. M. Chen, and J. W. Erickson, “Production by murine spleen cells of an activity stimulating the PHA responsiveness of thymus lymphocytes,” Cellular Immunology, vol. 17, no. 2, pp. 495–504, 1975.
- D. M. Chen and G. Di Sabato, “Further studies on the thymocyte stimulating factor,” Cellular Immunology, vol. 22, no. 2, pp. 211–224, 1976.
- S. B. Mizel and J. J. Farrar, “Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors,” Cellular Immunology, vol. 48, no. 2, pp. 433–436, 1979.
- J. Shaw, V. Monticone, G. Mills, and V. Paetkau, “Effects of costimulator on immune responses in vitro,” Journal of Immunology, vol. 120, no. 6, pp. 1974–1980, 1978.
- I. Yron, T. A. Wood, P. J. Spiess, and S. A. Rosenberg, “In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors,” Journal of Immunology, vol. 125, no. 1, pp. 238–245, 1980.
- M. T. Lotze, E. A. Grimm, and A. Mazumder, “Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor,” Cancer Research, vol. 41, no. 11 I, pp. 4420–4425, 1981.
- C. S. Henney, K. Kuribayashi, D. E. Kern, and S. Gillis, “Interleukin-2 augments natural killer cell activity,” Nature, vol. 291, no. 5813, pp. 335–338, 1981.
- M. Malkovsky, B. Loveland, and M. North, “Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes,” Nature, vol. 325, no. 6101, pp. 262–265, 1987.
- T. A. Waldmann, C. K. Goldman, and R. J. Robb, “Expression of interleukin 2 receptors on activated human B cells,” Journal of Experimental Medicine, vol. 160, no. 5, pp. 1450–1466, 1984.
- T. R. Mosmann, H. Cherwinski, and M. W. Bond, “Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins,” Journal of Immunology, vol. 136, no. 7, pp. 2348–2357, 1986.
- S. A. Rosenberg, M. T. Lotze, and L. M. Muul, “A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” New England Journal of Medicine, vol. 316, no. 15, pp. 889–897, 1987.
- D. E. Webb, H. A. Austin, A. Belldegrun, E. Vaughan, W. M. Linehan, and S. A. Rosenberg, “Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer,” Clinical Nephrology, vol. 30, no. 3, pp. 141–145, 1988.
- T. L. Ratliff, E. O. Haaff, and W. J. Catalona, “Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer,” Clinical Immunology and Immunopathology, vol. 40, no. 2, pp. 375–379, 1986.
- E. O. Haaff, W. J. Catalona, and T. L. Ratliff, “Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG,” Journal of Urology, vol. 136, no. 4, pp. 970–974, 1986.
- W. H. De Jong, E. C. De Boer, A. P. M. Van Der Meijden et al., “Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guerin,” Cancer Immunology Immunotherapy, vol. 31, no. 3, pp. 182–186, 1990.
- A. Böhle, C. Nowe, A. J. Ulmer et al., “Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma,” Cytokine, vol. 2, no. 3, pp. 175–181, 1990.
- E. C. De Boer, W. H. De Jong, P. A. Steerenberg et al., “Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guerine,” In Vivo, vol. 5, no. 6, pp. 671–678, 1991.
- E. C. De Boer, W. H. De Jong, P. A. Steerenberg et al., “Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer,” Cancer Immunology Immunotherapy, vol. 34, no. 5, pp. 306–312, 1992.
- D. Balbay, M. Bakkaloglu, H. Özen et al., “Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy,” Urology, vol. 43, no. 2, pp. 187–190, 1994.
- T. M. De Reijke, E. C. De Boer, K. H. Kurth, and D. H. J. Schamhart, “Urinary interleukin-2 monitoring during prolonged bacillus Calmette- Guerin treatment: can it predict the optimal number of instillations?” Journal of Urology, vol. 161, no. 1, pp. 67–71, 1999.
- K. Taniguchi, S. Koga, M. Nishikido et al., “Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer,” Clinical and Experimental Immunology, vol. 115, no. 1, pp. 131–135, 1999.
- C. Magno, D. Melloni, A. Galì et al., “The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2,” Immunology Letters, vol. 81, no. 3, pp. 235–238, 2002.
- G. Pizza, G. Severini, and D. Menniti, “Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report,” International Journal of Cancer, vol. 34, no. 3, pp. 359–367, 1984.
- K. E. Lee, G. H. Weiss, R. W. O'Donnell, and A. T. K. Cockett, “Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette Guerin and systemic Interleukin 2,” Journal of Urology, vol. 137, no. 6, pp. 1270–1273, 1987.
- S. Ikemoto, M. Kamizuru, S. Wada, S. Nishio, T. Kishimoto, and M. Maekawa, “Combined effect of interleukin 2 and Bacillus Calmette-Guerin in the therapy of mice with transitional cell carcinoma,” Urologia Internationalis, vol. 47, no. 4, pp. 250–254, 1991.
- D. R. Riggs, W. F. Tarry, J. I. DeHaven, J. Sosnowski, and D. L. Lamm, “Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy,” Journal of Urology, vol. 147, no. 1, pp. 212–214, 1992.
- A. Tubaro, F. Velotti, A. Stoppacciaro et al., “Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: a phase IB study,” Cancer, vol. 68, no. 1, pp. 56–61, 1991.
- P. A. Merguerian, L. Donahue, and A. T. K. Cockett, “Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report,” Journal of Urology, vol. 137, no. 2, pp. 216–219, 1987.
- E. Huland and H. Huland, “Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma,” Cancer Research, vol. 49, no. 19, pp. 5469–5474, 1989.
- A. T. K. Cockett, R. S. Davis, L. R. Cos, and L. L. Wheeless, “Bacillus calmette-guerin and interleukin-2 for treatment of superficial bladder cancer,” Journal of Urology, vol. 146, no. 3, pp. 766–770, 1991.
- L. G. Gomella, D. E. McGinnis, E. C. Lattime et al., “Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study,” Cancer Biotherapy, vol. 8, no. 3, pp. 223–227, 1993.
- W. Den Otter, Z. Dobrowolski, A. Bugajski et al., “Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients,” Journal of Urology, vol. 159, no. 4, pp. 1183–1186, 1998.
- M. A. O'Donnell, A. Aldovini, R. B. Duda et al., “Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes,” Infection and Immunity, vol. 62, no. 6, pp. 2508–2514, 1994.
- P. J. Murray, A. Aldovini, and R. A. Young, “Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 2, pp. 934–939, 1996.
- L. Slobbe, E. Lockhart, M. A. O'Donnell, C. Mackintosh, G. De Lisle, and G. Buchan, “An in vivo comparison of bacillus Calmette-Guerin (BCG) and cytokine- secreting BCG vaccines,” Immunology, vol. 96, no. 4, pp. 517–523, 1999.
- H. Yamada, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita, “Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2,” Journal of Urology, vol. 164, no. 2, pp. 526–531, 2000.
- Y. Luo, X. Chen, A. Szilvasi, and M. A. O'Donnell, “Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity,” Molecular Immunology, vol. 37, no. 9, pp. 527–536, 2000.
- S. L. Young, M. A. O'Donnell, and G. S. Buchan, “IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosupression to elicit a Type 1 immune response,” International Immunology, vol. 14, no. 7, pp. 793–800, 2002.
- Y. G. Li, Z. P. Wang, J. Q. Tian et al., “Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of t-lymphocyte in human bladder tumor cell s in vitro,” Cancer Investigation, vol. 27, no. 9, pp. 909–917, 2009.
- X. Huang, H. S. Yu, Z. Chen, J. L. Li, Z. M. Hu, and J. M. Gao, “A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall,” Chinese Journal of Cancer, vol. 29, no. 6, pp. 611–616, 2010.
- X. Zhang, X. Shi, J. Li et al., “Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells,” Urology, vol. 78, no. 3, pp. 722.el–722.e6, 2011.
- H. L. Wong, D. E. Wilson, J. C. Jenson, P. C. Familletti, D. L. Stremlo, and M. K. Gately, “Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro,” Cellular Immunology, vol. 111, no. 1, pp. 39–54, 1988.
- M. Kobayashi, L. Fitz, M. Ryan et al., “Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes,” Journal of Experimental Medicine, vol. 170, no. 3, pp. 827–845, 1989.
- A. S. Stern, F. J. Podlaski, J. D. Hulmes et al., “Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6808–6812, 1990.
- M. K. Gately, B. B. Desai, A. G. Wolitzky et al., “Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor),” Journal of Immunology, vol. 147, no. 3, pp. 874–882, 1991.
- U. Gubler, A. O. Chua, D. S. Schoenhaut et al., “Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 10, pp. 4143–4147, 1991.
- D. S. Schoenhaut, A. O. Chua, A. G. Wolitzky et al., “Cloning and expression of murine IL-12,” Journal of Immunology, vol. 148, no. 11, pp. 3433–3440, 1992.
- B. B. Desai, P. M. Quinn, A. G. Wolitzky, P. K. A. Mongini, R. Chizzonite, and M. K. Gately, “IL-12 receptor. II. Distribution and regulation of receptor expression,” Journal of Immunology, vol. 148, no. 10, pp. 3125–3132, 1992.
- R. Manetti, P. Parronchi, M. G. Giudizi et al., “Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells,” Journal of Experimental Medicine, vol. 177, no. 4, pp. 1199–1204, 1993.
- S. E. Macatonia, N. A. Hosken, M. Litton et al., “Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells,” Journal of Immunology, vol. 154, no. 10, pp. 5071–5079, 1995.
- M. K. Gately, A. G. Wolitzky, P. M. Quinn, and R. Chizzonite, “Regulation of human cytolytic lymphocyte responses by interleukin-12,” Cellular Immunology, vol. 143, no. 1, pp. 127–142, 1992.
- K. Collison, S. Saleh, R. Parhar et al., “Evidence for IL-12-activated Ca2+ and tyrosine signaling pathways in human neutrophils,” Journal of Immunology, vol. 161, no. 7, pp. 3737–3745, 1998.
- G. R. Yeaman, J. E. Collins, J. K. Currie, P. M. Guyre, C. R. Wira, and M. W. Fanger, “IFN-γ is produced by polymorphonuclear neutrophils in human uterine endometrium and by cultured peripheral blood polymorphonuclear neutrophils,” Journal of Immunology, vol. 160, no. 10, pp. 5145–5153, 1998.
- E. E. Voest, B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman, “Inhibition of angiogenesis in vivo by interleukin 12,” Journal of the National Cancer Institute, vol. 87, no. 8, pp. 581–586, 1995.
- S. Dias, R. Boyd, and F. Balkwill, “IL-12 regulates VEGF and MMPs in a murine breast cancer model,” International Journal of Cancer, vol. 78, no. 3, pp. 361–365, 1998.
- C. M. Coughlin, K. E. Salhany, M. S. Gee et al., “Tumor cell responses to IFNγ affect tumorigenicity and response to IL- 12 therapy and antiangiogenesis,” Immunity, vol. 9, no. 1, pp. 25–34, 1998.
- C. M. Coughlin, K. E. Salhany, M. Wysocka et al., “Interleukin-12, and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1441–1452, 1998.
- W. Hashimoto, T. Osaki, H. Okamura et al., “Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin- induced tumor apoptosis, respectively,” Journal of Immunology, vol. 163, no. 2, pp. 583–589, 1999.
- T. Kawamura, K. Takeda, S. K. Mendiratta et al., “Cutting edge: critical role of NK1 T cells in IL-12-induced immune responses in vivo,” Journal of Immunology, vol. 160, no. 1, pp. 16–19, 1998.
- M. J. Brunda, L. Luistro, R. R. Warrier et al., “Antitumor and antimetastatic activity of interleukin 12 against murine tumors,” Journal of Experimental Medicine, vol. 178, no. 4, pp. 1223–1230, 1993.
- C. L. Nastala, H. D. Edington, T. G. McKinney et al., “Recombinant IL-12 administration induces tumor regression in association with IFN-γ production,” Journal of Immunology, vol. 153, no. 4, pp. 1697–1706, 1994.
- B. A. Teicher, G. Ara, D. Buxton, J. Leonard, and R. G. Schaub, “Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma,” Clinical Cancer Research, vol. 3, no. 9, pp. 1661–1667, 1997.
- B. A. Teicher, G. Ara, D. Buxton, J. Leonard, and R. G. Schaub, “Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine lewis lung carcinoma,” Radiation Oncology Investigations, vol. 6, no. 2, pp. 71–80, 1998.
- M. A. O'Donnell, Y. Luo, S. E. Hunter, X. Chen, L. L. Hayes, and S. K. Clinton, “Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity,” Journal of Urology, vol. 171, no. 3, pp. 1330–1335, 2004.
- R. S. Zagozdzon, A. Giermasz, J. Golab, T. Stoklosa, A. Jalili, and M. Jakóbisiak, “The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production,” Cancer Letters, vol. 147, no. 1-2, pp. 67–75, 1999.
- R. Zagozdzon, J. Golab, K. Mucha, B. Foroncewicz, and M. Jakobisiak, “Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo,” International Journal of Molecular Medicine, vol. 4, no. 6, pp. 645–648, 1999.
- J. Golab, R. Zagozdzon, K. Kozar et al., “Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo,” Oncology Reports, vol. 7, no. 1, pp. 177–181, 2000.
- B. A. Teicher, G. Ara, K. Menon, and R. G. Schaub, “In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment,” International Journal of Cancer, vol. 65, no. 1, pp. 80–84, 1996.
- F. H. L. Lieu, T. S. Hawley, A. Z. C. Fong, and R. G. Hawley, “Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy,” Cancer Gene Therapy, vol. 4, no. 3, pp. 167–175, 1997.
- J. L. Bramson, M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham, “Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12,” Human Gene Therapy, vol. 7, no. 16, pp. 1995–2002, 1996.
- C. L. Addison, J. L. Bramson, M. M. Hitt, W. J. Muller, J. Gauldie, and F. L. Graham, “Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors,” Gene Therapy, vol. 5, no. 10, pp. 1400–1409, 1998.
- J. B. Meko, J. H. Yim, K. Tsung, and J. A. Norton, “High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12,” Cancer Research, vol. 55, no. 21, pp. 4765–4770, 1995.
- L. Zitvogel, H. Tahara, Q. Cai et al., “Construction and characterization of retroviral vectors expressing biologically active human interleukin-12,” Human Gene Therapy, vol. 5, no. 12, pp. 1493–1506, 1994.
- M. A. O'Donnell, Y. Luo, X. Chen, A. Szilvasi, S. E. Hunter, and S. K. Clinton, “Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guerin,” Journal of Immunology, vol. 163, no. 8, pp. 4246–4252, 1999.
- J. Riemensberger, A. Böhle, and S. Brandau, “IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer,” Clinical and Experimental Immunology, vol. 127, no. 1, pp. 20–26, 2002.
- M. A. O'Donnell, Y. Luo, S. E. Hunter, X. Chen, L. L. Hayes, and S. K. Clinton, “The essential role of interferon-γ during interleukin-12 therapy for murine transitional cell carcinoma of the bladder,” Journal of Urology, vol. 171, no. 3, pp. 1336–1342, 2004.
- M. Horinaga, K. M. Harsch, R. Fukuyama, W. Heston, and W. Larchian, “Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model,” Urology, vol. 66, no. 2, pp. 461–466, 2005.
- D. A. Zaharoff, B. S. Hoffman, H. B. Hooper et al., “Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12,” Cancer Research, vol. 69, no. 15, pp. 6192–6199, 2009.
- J. Cohen, “IL-12 deaths: explanation and a puzzle,” Science, vol. 270, no. 5238, p. 908, 1995.
- M. B. Atkins, M. J. Robertson, M. Gordon et al., “Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies,” Clinical Cancer Research, vol. 3, no. 3, pp. 409–417, 1997.
- M. J. Robertson, C. Cameron, M. B. Atkins et al., “Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer,” Clinical Cancer Research, vol. 5, no. 1, pp. 9–16, 1999.
- J. A. Gollob, J. W. Mier, K. Veenstra et al., “Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response,” Clinical Cancer Research, vol. 6, no. 5, pp. 1678–1692, 2000.
- J. A. Hurteau, J. A. Blessing, S. L. DeCesare, and W. T. Creasman, “Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study,” Gynecologic Oncology, vol. 82, no. 1, pp. 7–10, 2001.
- R. J. Motzer, A. Rakhit, J. A. Thompson et al., “Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-α2a for patients with advanced renal cell carcinoma,” Journal of Interferon and Cytokine Research, vol. 21, no. 4, pp. 257–263, 2001.
- R. Lenzi, M. Rosenblum, C. Verschraegen et al., “Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma,” Clinical Cancer Research, vol. 8, no. 12, pp. 3686–3695, 2002.
- R. Lenzi, R. Edwards, C. June et al., “Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma,” Journal of Translational Medicine, vol. 5, article 66, 2007.
- A. Younes, B. Pro, M. J. Robertson et al., “Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease,” Clinical Cancer Research, vol. 10, no. 16, pp. 5432–5438, 2004.
- J. A. Gollob, K. G. Veenstra, R. A. Parker et al., “Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma,” Journal of Clinical Oncology, vol. 21, no. 13, pp. 2564–2573, 2003.
- C. F. Eisenbeis, G. B. Lesinski, M. Anghelina et al., “Phase I study of the sequential combination of interleukin-12 and iterferon afa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8835–8844, 2005.
- G. R. Weiss, M. A. O'Donnell, K. Loughlin, K. Zonno, R. J. Laliberte, and M. L. Sherman, “Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder,” Journal of Immunotherapy, vol. 26, no. 4, pp. 343–348, 2003.
- R. Nadler, Y. Luo, W. Zhao et al., “Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity,” Clinical and Experimental Immunology, vol. 131, no. 2, pp. 206–216, 2003.
- Y. Luo, R. Han, D. P. Evanoff, and X. Chen, “Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells,” Clinical and Experimental Immunology, vol. 160, no. 3, pp. 359–368, 2010.
- D. F. Fiorentino, M. W. Bond, and T. R. Mosmann, “Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones,” Journal of Experimental Medicine, vol. 170, no. 6, pp. 2081–2095, 1989.
- D. F. Fiorentino, A. Zlotnik, P. Vieira et al., “IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells,” Journal of Immunology, vol. 146, no. 10, pp. 3444–3451, 1991.
- T. A. Ferguson, P. Dube, and T. S. Griffith, “Regulation of contact hypersensitivity by interleukin 10,” Journal of Experimental Medicine, vol. 179, no. 5, pp. 1597–1604, 1994.
- B. K. Halak, H. C. Maguire, and E. C. Lattime, “Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site,” Cancer Research, vol. 59, no. 4, pp. 911–917, 1999.
- E. C. Lattime, M. J. Mastrangelo, O. Bagasra, W. Li, and D. Berd, “Expression of cytokine mRNA in human melanoma tissues,” Cancer Immunology Immunotherapy, vol. 41, no. 3, pp. 151–156, 1995.
- S. Kruger-Krasagakes, K. Krasagakis, C. Garbe et al., “Expression of interleukin 10 in human melanoma,” British Journal of Cancer, vol. 70, no. 6, pp. 1182–1185, 1994.
- M. Huang, J. Wang, P. Lee et al., “Human non-small cell lung cancer cells express a type 2 cytokine pattern,” Cancer Research, vol. 55, no. 17, pp. 3847–3853, 1995.
- H. Nakagomi, P. Pisa, E. K. Pisa et al., “Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma,” International Journal of Cancer, vol. 63, no. 3, pp. 366–371, 1995.
- T. R. Mosmann, J. H. Schumacher, D. F. Fiorentino, J. Leverah, K. W. Moore, and M. W. Bond, “Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay,” Journal of Immunology, vol. 145, no. 9, pp. 2938–2945, 1990.
- A. O'Garra, G. Stapleton, V. Dhar et al., “Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10,” International Immunology, vol. 2, no. 9, pp. 821–832, 1990.
- R. De Waal Malefyt, J. Abrams, B. Bennett, C. G. Figdor, and J. E. De Vries, “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209–1220, 1991.
- Z. Qin, G. Noffz, M. Mohaupt, and T. Blankenstein, “Interleukin-10 prevents dendritic cell accumulation and vaccination with Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Tumor Cells,” Journal of Immunology, vol. 159, no. 2, pp. 770–776, 1997.
- G. Richter, S. Kruger-Krasagakes, G. Hein et al., “Interleukin 10 transfected into chinese hamster ovary cells prevents tumor growth and macrophage infiltration,” Cancer Research, vol. 53, no. 18, pp. 4134–4137, 1993.
- K. Steinbrink, M. Wölfl, H. Jonuleit, J. Knop, and A. H. Enk, “Induction of tolerance by IL-10-treated dendritic cells,” Journal of Immunology, vol. 159, no. 10, pp. 4772–4780, 1997.
- R. De Waal Malefyt, J. Haanen, H. Spits et al., “Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression,” Journal of Experimental Medicine, vol. 174, no. 4, pp. 915–924, 1991.
- L. Ding, P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach, “IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression,” Journal of Immunology, vol. 151, no. 3, pp. 1224–1234, 1993.
- F. Willems, A. Marchant, J. P. Delville et al., “Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes,” European Journal of Immunology, vol. 24, no. 4, pp. 1007–1009, 1994.
- H. Groux, A. O'Garra, M. Bigler et al., “A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,” Nature, vol. 389, no. 6652, pp. 737–742, 1997.
- E. Cenci, L. Romani, A. Mencacci et al., “Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans,” European Journal of Immunology, vol. 23, no. 5, pp. 1034–1038, 1993.
- K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001.
- N. A. Bockholt, M. J. Knudson, J. R. Henning et al., “Anti-IL-10R1 monoclonal antibody enhances BCG-induced TH1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer,” The Journal of Urology, vol. 187, pp. 2228–2235, 2012.